Sacituzumab Govitecan

Phase 2Active

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Anatomic Stage IV Breast Cancer AJCC v8

Conditions

Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8

Trial Timeline

Jun 8, 2021 → Dec 1, 2028

NCT ID

NCT04647916

About Sacituzumab Govitecan

Sacituzumab Govitecan is a phase 2 stage product being developed by Gilead Sciences for Anatomic Stage IV Breast Cancer AJCC v8. The current trial status is active. This product is registered under clinical trial identifier NCT04647916. Target conditions include Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (16)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06923826	Phase 2	Recruiting	Apr 15, 2025	Apr 1, 2030	Salivary Gland Cancer
NCT06665178	Phase 2	Recruiting	Mar 31, 2025	Dec 1, 2028	Breast Cancer
NCT06235216	Phase 2	Recruiting	Sep 13, 2024	Dec 1, 2027	Differentiated Thyroid Cancer
NCT06329869	Phase 2	Recruiting	Aug 1, 2024	Nov 1, 2027	Esophageal Squamous Cell Carcinoma
NCT06263543	Phase 2	Recruiting	Jun 17, 2024	Dec 1, 2026	Breast Cancer
NCT06123468	Phase 1/2	Completed	Apr 17, 2024	Jan 7, 2026	Esophagogastric Adenocarcinoma
NCT05833867	Phase 1	Recruiting	Apr 1, 2024	Oct 1, 2027	Localized Muscle Invasive Bladder Urothelial Carcinoma
NCT06028932	Phase 2	Active	Jan 8, 2024	Nov 1, 2027	Ovarian Carcinoma
NCT05552001	Phase 3	Recruiting	Oct 5, 2023	May 6, 2028	Triple Negative Breast Cancer
NCT05884320	Phase 2	Recruiting	Jul 27, 2023	Jul 31, 2028	Gland
NCT05581589	Phase 2	Recruiting	Jun 15, 2023	Apr 30, 2027	Muscle Invasive Bladder Carcinoma
NCT05838521	Phase 2	Recruiting	Jun 2, 2023	Jun 1, 2028	Cervical Cancer
NCT04647916	Phase 2	Active	Jun 8, 2021	Dec 1, 2028	Anatomic Stage IV Breast Cancer AJCC v8
NCT04251416	Phase 2	Active	Mar 17, 2020	Feb 1, 2027	Endometrial Carcinoma
NCT03995706	Phase 1	Completed	Jul 17, 2019	Mar 20, 2024	Glioblastoma
NCT03725761	Phase 2	Active	Oct 24, 2018	Sep 1, 2027	Prostate Cancer

Competing Products

13 competing products in Anatomic Stage IV Breast Cancer AJCC v8

See all competitors

Product	Company	Stage	Hype Score
Abemaciclib + Niraparib Tosylate Monohydrate	Eli Lilly	Phase 1	33
Capivasertib + Ceralasertib + Durvalumab + Olaparib + Selumetinib	AstraZeneca	Phase 2	52
Pembrolizumab + Tamoxifen + Vorinostat	Merck	Phase 2	52
Carboplatin + Docetaxel + Fulvestrant + Pertuzumab + Ribociclib + Trastuzumab + Tucatinib	Novartis	Phase 1/2	41
Lutetium Lu 177 Dotatate	Novartis	Phase 2	52
Anastrozole + Exemestane + Fulvestrant + Letrozole + Paclitaxel + Talimogene Laherparepvec + Tamoxifen + Nab paclitaxel + Gemcitabine + Carboplatin	Amgen	Phase 1	32
Anastrozole + Exemestane + Fulvestrant + Letrozole + Palbociclib + Tamoxifen	Pfizer	Phase 2	51
Abexinostat Tosylate + Fulvestrant + Palbociclib	Pfizer	Phase 1	32
Aromatase Inhibition Therapy	Bristol Myers Squibb	Pre-clinical	22
Pelareorep + Retifanlimab	Incyte	Phase 2	49
Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody	Imugene	Phase 1	25
Neratinib	Puma Biotechnology	Phase 2	44
Ivermectin + Balstilmab + Pembrolizumab	Agenus	Phase 1/2	33

Other Products from Gilead Sciences

Ranolazine + PlaceboApproved

Truvada + Atazanavir + RitonavirApproved

Truvada + efavirenzApproved

B/F/TAF + Atripla + B/F/TAF Placebo + Atripla PlaceboApproved

TDF + Placebo Vaginal Gel + Vaginal TFV Gel + Placebo TabletsApproved